Leishmania donovani Attenuates Dendritic Cell Trafficking to Lymph Nodes by Inhibiting C-Type Lectin Receptor 2 Expression via Transforming Growth Factor-β

Dendritic cells (DCs) play a key role in initiating T cell-mediated protective immunity against visceral leishmaniasis (VL), the second most lethal parasitic disease in the world. However, the T cell-inducing ability of DCs critically depends on the extent of DC migration to regional lymph nodes. ABSTRACT To initiate an antileishmanial adaptive immune response, dendritic cells (DCs) must carry Leishmania antigens from peripheral tissues to local draining lymph nodes. However, the migratory capacity of DCs is largely compromised during Leishmania donovani infection. The molecular mechanism underlying this defective DC migration is not yet fully understood. Here, we demonstrate that L. donovani infection impaired the lymph node homing ability of DCs by decreasing C-type lectin receptor 2 (CLEC-2) expression. L. donovani exerted this inhibitory effect by inducing transforming growth factor-β (TGF-β) secretion from DCs. Indeed, TGF-β produced in this manner inhibited nuclear factor-κB (NF-κB)-mediated CLEC-2 expression on DCs by activating c-Src. Notably, suppression of c-Src expression significantly improved the arrival of DCs in draining lymph nodes by preventing L. donovani-induced CLEC-2 downregulation on DCs. These findings reveal a unique mechanism by which L. donovani inhibits DC migration to lymph nodes and suggest a key role for TGF-β, c-Src, and CLEC-2 in regulating this process. IMPORTANCE Dendritic cells (DCs) play a key role in initiating T cell-mediated protective immunity against visceral leishmaniasis (VL), the second most lethal parasitic disease in the world. However, the T cell-inducing ability of DCs critically depends on the extent of DC migration to regional lymph nodes. Notably, the migration of DCs is reported to be impaired during VL. The cause of this impaired DC migration, however, remains ill-defined. Here, we provide the first evidence that L. donovani, the causative agent of VL, attenuates the lymph node homing capacity of DCs by decreasing C-type lectin receptor 2 (CLEC-2) expression on DCs. Additionally, we have demonstrated how L. donovani mediates this inhibitory effect. Overall, our work has revealed a unique mechanism underlying L. donovani-induced impairment of DC migration and suggests a potential strategy to improve antileishmanial T cell activity by increasing DC arrival in lymph nodes.

[1]  Sahil Kumar,et al.  Leishmania donovani Impedes Antileishmanial Immunity by Suppressing Dendritic Cells via the TIM-3 Receptor , 2022, mBio.

[2]  T. Petrova,et al.  The C5a-C5aR1 complement axis is essential for neutrophil recruitment to draining lymph nodes via high endothelial venules in cutaneous leishmaniasis. , 2022, Cell reports.

[3]  Qiaojun He,et al.  Optineurin modulates the maturation of dendritic cells to regulate autoimmunity through JAK2-STAT3 signaling , 2021, Nature Communications.

[4]  S. Watson,et al.  CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis , 2021, Frontiers in Immunology.

[5]  Neeraj Khatri,et al.  Runx proteins mediate protective immunity against Leishmania donovani infection by promoting CD40 expression on dendritic cells , 2020, PLoS pathogens.

[6]  Daniel J. Gaffney,et al.  Loss of IL-10 signaling in macrophages limits bacterial killing driven by prostaglandin E2 , 2019, The Journal of experimental medicine.

[7]  T. Alain,et al.  Translational profiling of macrophages infected with Leishmania donovani identifies mTOR- and eIF4A-sensitive immune-related transcripts , 2019, bioRxiv.

[8]  M. Shadab,et al.  EBI-3 Chain of IL-35 Along With TGF-β Synergistically Regulate Anti-leishmanial Immunity , 2019, Front. Immunol..

[9]  C. Brodskyn,et al.  Molecular Aspects of Dendritic Cell Activation in Leishmaniasis: An Immunobiological View , 2019, Front. Immunol..

[10]  Pradip Sen,et al.  Transforming growth factor‐&bgr;1 impairs lymph node homing of dendritic cells by downregulating C‐type lectin receptor‐2 expression , 2018, Cytokine.

[11]  Y. Henis,et al.  Cholesterol depletion enhances TGF-β Smad signaling by increasing c-Jun expression through a PKR-dependent mechanism , 2018, Molecular biology of the cell.

[12]  C. Ballantyne,et al.  Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity , 2018, Proceedings of the National Academy of Sciences.

[13]  B. Biswas,et al.  Fine-needle aspiration cytology of leishmanial lymphadenitis in an HIV-reactive patient: Report of a rare case , 2018, Tropical parasitology.

[14]  Z. Xia,et al.  Hyperglycaemia inhibits REG3A expression to exacerbate TLR3-mediated skin inflammation in diabetes , 2016, Nature Communications.

[15]  R. Reguera,et al.  Leishmania Uses Mincle to Target an Inhibitory ITAM Signaling Pathway in Dendritic Cells that Dampens Adaptive Immunity to Infection. , 2016, Immunity.

[16]  Y. Ozaki,et al.  New horizon in platelet function: with special reference to a recently-found molecule, CLEC-2 , 2016, Thrombosis Journal.

[17]  Neeraj Khatri,et al.  c-Src Suppresses Dendritic Cell Antitumor Activity via T Cell Ig and Mucin Protein-3 Receptor , 2016, The Journal of Immunology.

[18]  T. Nheu,et al.  SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor* , 2015, The Journal of Biological Chemistry.

[19]  Partha Palit,et al.  Cationic Liposomal Sodium Stibogluconate (SSG), a Potent Therapeutic Tool for Treatment of Infection by SSG-Sensitive and -Resistant Leishmania donovani , 2014, Antimicrobial Agents and Chemotherapy.

[20]  S. Narumiya,et al.  Prostanoid induces premetastatic niche in regional lymph nodes. , 2014, The Journal of clinical investigation.

[21]  W. L. DOS‐SANTOS,et al.  Leishmania amazonensis infection impairs dendritic cell migration from the inflammatory site to the draining lymph node , 2014, BMC Infectious Diseases.

[22]  J. Barnes,et al.  Deficiency of Lymph Node-Resident Dendritic Cells (DCs) and Dysregulation of DC Chemoattractants in a Malnourished Mouse Model of Leishmania donovani Infection , 2014, Infection and Immunity.

[23]  A. McKenzie,et al.  The IL-33/ST2 Axis Is Associated with Human Visceral Leishmaniasis and Suppresses Th1 Responses in the Livers of BALB/c Mice Infected with Leishmania donovani , 2013, mBio.

[24]  P. Scott,et al.  Leishmania mexicana Induces Limited Recruitment and Activation of Monocytes and Monocyte-Derived Dendritic Cells Early during Infection , 2012, PLoS neglected tropical diseases.

[25]  V. Kuchroo,et al.  Podoplanin-Rich Stromal Networks Induce Dendritic Cell Motility via Activation of the C-type Lectin Receptor CLEC-2 , 2012, Immunity.

[26]  K. Tsuchida,et al.  An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy , 2012, Laboratory Investigation.

[27]  H. Yoshiyama,et al.  Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 , 2012, Nature Immunology.

[28]  D. Sacks,et al.  The influence of early neutrophil-Leishmania interactions on the host immune response to infection , 2012, Front. Cell. Inf. Microbio..

[29]  W. Messersmith,et al.  Current status of SRC inhibitors in solid tumor malignancies. , 2011, The oncologist.

[30]  C. Chung,et al.  A novel mechanism of cytokine release in phagocytes induced by aggretin, a snake venom C‐type lectin protein, through CLEC‐2 ligation , 2010, Journal of thrombosis and haemostasis : JTH.

[31]  B. Saha,et al.  CD40 Expression Levels Modulate Regulatory T Cells in Leishmania donovani Infection , 2010, The Journal of Immunology.

[32]  I. Mellman,et al.  Mature dendritic cells use endocytic receptors to capture and present antigens , 2010, Proceedings of the National Academy of Sciences.

[33]  Kuo-I Lin,et al.  Absence of the Transcriptional Repressor Blimp-1 in Hematopoietic Lineages Reveals Its Role in Dendritic Cell Homeostatic Development and Function1 , 2009, The Journal of Immunology.

[34]  B. Pasche,et al.  Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis , 2008, Current opinion in rheumatology.

[35]  R. Peeling,et al.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? , 2007, Nature Reviews Microbiology.

[36]  C. Engwerda,et al.  Balancing immunity and pathology in visceral leishmaniasis , 2007, Immunology and cell biology.

[37]  N. Glaichenhaus,et al.  Lymph Node Resident Rather Than Skin-Derived Dendritic Cells Initiate Specific T Cell Responses after Leishmania major Infection , 2006, The Journal of Immunology.

[38]  P. Kaye,et al.  Distinct roles for IL‐6 and IL‐12p40 in mediating protection against Leishmania donovani and the expansion of IL‐10+ CD4+ T cells , 2006, European journal of immunology.

[39]  Syamal Roy,et al.  Leishmania donovani Affects Antigen Presentation of Macrophage by Disrupting Lipid Rafts1 , 2005, The Journal of Immunology.

[40]  P. Murray.  The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Baldwin,et al.  Dendritic Cell Populations in Leishmania major-Infected Skin and Draining Lymph Nodes , 2004, Infection and Immunity.

[42]  S. Narumiya,et al.  Prostaglandin D2 inhibits the production of interleukin‐12 in murine dendritic cells through multiple signaling pathways , 2003, European journal of immunology.

[43]  P. Kaye,et al.  Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis , 2002, Nature Immunology.

[44]  Peter J. Murray,et al.  Shaping Gene Expression in Activated and Resting Primary Macrophages by IL-101 , 2002, The Journal of Immunology.

[45]  R. Förster,et al.  Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. , 2002, Blood.

[46]  A. Ponte-Sucre,et al.  Leishmania major lipophosphoglycan modulates the phenotype and inhibits migration of murine Langerhans cells , 2001, Immunology.

[47]  A. Tabares,et al.  Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection. , 2001, Experimental parasitology.

[48]  P. Das,et al.  Successful Therapy of Lethal Murine Visceral Leishmaniasis with Cystatin Involves Up-Regulation of Nitric Oxide and a Favorable T Cell Response1 , 2001, The Journal of Immunology.

[49]  Clare L. Bennett,et al.  Silent infection of bone marrow‐derived dendritic cells by Leishmania mexicana amastigotes , 2001, European journal of immunology.

[50]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[51]  M. Mayo,et al.  Interleukin-10 Signaling Blocks Inhibitor of κB Kinase Activity and Nuclear Factor κB DNA Binding* , 1999, The Journal of Biological Chemistry.

[52]  M. Mayo,et al.  Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. , 1999, The Journal of biological chemistry.

[53]  C. Heldin,et al.  Identification and Functional Characterization of a Smad Binding Element (SBE) in the JunB Promoter That Acts as a Transforming Growth Factor-β, Activin, and Bone Morphogenetic Protein-inducible Enhancer* , 1998, The Journal of Biological Chemistry.

[54]  V. Rodrigues,et al.  Transforming growth factor beta and immunosuppression in experimental visceral leishmaniasis. , 1998, Infection and immunity.

[55]  O. Martínez-Maza,et al.  Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. , 1996, Journal of immunology.

[56]  G. H. Coombs,et al.  A quick, simple method for purifying Leishmania mexicana amastigotes in large numbers , 1981, Parasitology.

[57]  of Infection , 2022 .